Investigation of Vaccine-Induced Immune Response After Vaccination Against Respiratory Viruses in Immunocompromised Patients With or Without Hemato-Oncological Diseases (RESPONSE): Protocol for a Prospective Cohort Study
JMIR Research Protocols · 23.07.2026 · 15 · e88520
DOI: 10.2196/88520 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift JMIR Research Protocols, online erschienen am 23.07.2026. Verfasst von Eloísa Felipe Fumero und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycolo…. Hauptthemen laut MEDLINE: Immunocompromised Host, Hematologic Neoplasms, COVID-19, COVID-19 Vaccines. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Infections with respiratory viruses such as SARS-CoV-2 and influenza are significant international public health concerns. While patients with cancer remain the most vulnerable group, they show poor vaccine response in general. Immunological data in this population are limited and mainly focus on serological parameters. However, in these patients, cellular, and especially T-cell, responses often seem to be induced more reliably than humoral responses.
Objective
To gain further insights into vaccine-induced immunity, the RESPONSE study will analyze the effect of early and late booster vaccination on humoral and cellular responses, with special focus on T cell–induced immune responses. In addition, we aim to investigate factors influencing humoral and cellular vaccine-induced immunity in patients with hematological and oncological malignancies, including state of disease, treatment, and demographic factors.
Methods
Humoral immune responses will be assessed by measuring binding and neutralizing antibodies using standardized assays. Cellular immunity will be evaluated using functional assays such as flow cytometry and FluoroSpot, as well as in-depth analyses using additional exploratory assays as appropriate. Immune responses will be correlated with clinical parameters, including disease status, treatment, and demographic factors.
Results
This study was initiated following ethics approval and is currently recruiting participants. Enrollment commenced on March 25, 2025, and is ongoing, whereas biosample collection and follow-up visits are nearing completion for most participants. Final data cleaning, dataset integration, and statistical analyses of adaptive immune responses are planned from the third quarter of 2026 onward.
Conclusions
This study intends to lay a foundation for a structured translational research platform on vaccination to aim for best protection from infection by different respiratory pathogens. Long-term objectives are reaching best possible protection from vaccine-preventable disease with a first focus on influenza infection. In addition, we plan to investigate vaccine-induced immune responses to the recently approved respiratory syncytial virus vaccine using this platform and possibly extend this to further vaccines in the future. Urgent questions, such as the influence of different targeted therapies on vaccine immune response, will be part of these projects. Trial Registration ClinicalTrials.gov NCT06612515; https://clinicaltrials.gov/study/NCT06612515 International Registered Report Identifier (IRRID) DERR1-10.2196/88520
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), University Hospital Cologne, Cologne, Germany.
- Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
- German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.
- Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
- Clinical Trials Centre Cologne (ZKS Köln), University of Cologne, Cologne, Germany.
ORCID-Profile: Eloísa Felipe Fumero, Jannik Stemler, Rosanne Sprute, Katja M Sauer, Henning Gruell, Christoph Kreer, Florian Klein, Sebastian J Theobald, Jan Rybniker, Oliver A Cornely, Lara Kappes, Louise M Cremer, Sibylle C Mellinghoff
Zitieren
APA
Felipe Fumero, E., Stemler, J., Sprute, R., Sauer, K. M., Gruell, H., Kreer, C., Klein, F., Theobald, S. J., Rybniker, J., Cornely, O. A., Kappes, L., Cremer, L. M., & Mellinghoff, S. C. (2026). Investigation of Vaccine-Induced Immune Response After Vaccination Against Respiratory Viruses in Immunocompromised Patients With or Without Hemato-Oncological Diseases (RESPONSE): Protocol for a Prospective Cohort Study. JMIR Research Protocols, 15, e88520. https://doi.org/10.2196/88520
Vancouver
Felipe Fumero E, Stemler J, Sprute R, Sauer KM, Gruell H, Kreer C, et al. Investigation of Vaccine-Induced Immune Response After Vaccination Against Respiratory Viruses in Immunocompromised Patients With or Without Hemato-Oncological Diseases (RESPONSE): Protocol for a Prospective Cohort Study. JMIR Research Protocols. 2026;15:e88520. doi:10.2196/88520
BibTeX
@article{FelipeFumero2026,
author = {Felipe Fumero, Eloísa and Stemler, Jannik and Sprute, Rosanne and Sauer, Katja M and Gruell, Henning and Kreer, Christoph and Klein, Florian and Theobald, Sebastian J and Rybniker, Jan and Cornely, Oliver A and Kappes, Lara and Cremer, Louise M and Mellinghoff, Sibylle C},
title = {Investigation of Vaccine-Induced Immune Response After Vaccination Against Respiratory Viruses in Immunocompromised Patients With or Without Hemato-Oncological Diseases (RESPONSE): Protocol for a Prospective Cohort Study},
journal = {JMIR Research Protocols},
year = {2026},
volume = {15},
pages = {e88520},
doi = {10.2196/88520}
}
EUVIMED